A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Zagociguat (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Adverse reactions
- Acronyms CIAS
- Sponsors Cyclerion Therapeutics
- 18 Aug 2022 Status changed from active, no longer recruiting to completed.
- 28 Jul 2022 According to a Cyclerion Therapeutics media release, topline data from this study will discuss during a live webinar.
- 28 Jul 2022 Results published in the Media Release